3 results
Approved WMOCompleted
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…
Not approvedWill not start
This study investigates the safety and tolerability of deferoxamine use in patients with aneurysma subarachnoid hemorrhage.
Approved WMORecruiting
This study investigates the effectivity and the safety of deferoxamine use in patients with aneurysma subarachnoidhemorrhage.